279 related articles for article (PubMed ID: 37805959)
1. Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.
Shafaghat Z; Ghomi AK; Khorramdelazad H; Safari E
Inflammopharmacology; 2023 Dec; 31(6):3005-3020. PubMed ID: 37805959
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19.
Korb VG; Schultz IC; Beckenkamp LR; Wink MR
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175571
[TBL] [Abstract][Full Text] [Related]
3. Possible role of purinergic signaling in COVID-19.
Franciosi MLM; Lima MDM; Schetinger MRC; Cardoso AM
Mol Cell Biochem; 2021 Aug; 476(8):2891-2898. PubMed ID: 33740184
[TBL] [Abstract][Full Text] [Related]
4. High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity.
da Silva GB; Manica D; da Silva AP; Kosvoski GC; Hanauer M; Assmann CE; Simões JLB; Pillat MM; de Lara JD; Marafon F; Bertollo AG; Mingoti MED; Gavioli J; Réus GZ; de Oliveira GG; Ignácio ZM; Bagatini MD
J Mol Med (Berl); 2022 Apr; 100(4):645-663. PubMed ID: 35249135
[TBL] [Abstract][Full Text] [Related]
5. Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2.
Dos Anjos F; Simões JLB; Assmann CE; Carvalho FB; Bagatini MD
J Immunol Res; 2020; 2020():8632048. PubMed ID: 33299899
[TBL] [Abstract][Full Text] [Related]
6. Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19.
Nadeali Z; Mohammad-Rezaei F; Aria H; Nikpour P
Life Sci; 2022 May; 297():120482. PubMed ID: 35288174
[TBL] [Abstract][Full Text] [Related]
7. Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue.
Leão Batista Simões J; Fornari Basso H; Cristine Kosvoski G; Gavioli J; Marafon F; Elias Assmann C; Barbosa Carvalho F; Dulce Bagatini M
Int Immunopharmacol; 2021 Nov; 100():108150. PubMed ID: 34537482
[TBL] [Abstract][Full Text] [Related]
8. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Hasan D; Shono A; van Kalken CK; van der Spek PJ; Krenning EP; Kotani T
Purinergic Signal; 2022 Mar; 18(1):13-59. PubMed ID: 34757513
[TBL] [Abstract][Full Text] [Related]
9. The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2.
Hernandez CA; Eugenin EA
Curr Opin Pharmacol; 2023 Dec; 73():102404. PubMed ID: 37734241
[TBL] [Abstract][Full Text] [Related]
10. Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation.
Díaz-García E; García-Tovar S; Alfaro E; Zamarrón E; Mangas A; Galera R; Ruíz-Hernández JJ; Solé-Violán J; Rodríguez-Gallego C; Van-Den-Rym A; Pérez-de-Diego R; Nanwani-Nanwani K; López-Collazo E; García-Rio F; Cubillos-Zapata C
Front Immunol; 2022; 13():847894. PubMed ID: 35173744
[TBL] [Abstract][Full Text] [Related]
11. Alterations in CD39/CD73 axis of T cells associated with COVID-19 severity.
Dorneles GP; Teixeira PC; da Silva IM; Schipper LL; Santana Filho PC; Rodrigues Junior LC; Bonorino C; Peres A; Fonseca SG; Monteiro MC; Boeck CR; Eller S; Oliveira TF; Wendland EM; Romão PRT
J Cell Physiol; 2022 Aug; 237(8):3394-3407. PubMed ID: 35754396
[TBL] [Abstract][Full Text] [Related]
12. Extracellular ATP signaling and clinical relevance.
Dou L; Chen YF; Cowan PJ; Chen XP
Clin Immunol; 2018 Mar; 188():67-73. PubMed ID: 29274390
[TBL] [Abstract][Full Text] [Related]
13. Targeting adenosinergic pathway and adenosine A
Abouelkhair MA
Med Hypotheses; 2020 Nov; 144():110012. PubMed ID: 32590324
[TBL] [Abstract][Full Text] [Related]
14. Unlocking the Potential of Purinergic Signaling in Transplantation.
Zeiser R; Robson SC; Vaikunthanathan T; Dworak M; Burnstock G
Am J Transplant; 2016 Oct; 16(10):2781-2794. PubMed ID: 27005321
[TBL] [Abstract][Full Text] [Related]
15. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
Zarei M; Sahebi Vaighan N; Ziai SA
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):633-643. PubMed ID: 34647511
[TBL] [Abstract][Full Text] [Related]
16. Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome.
Simões JLB; Bagatini MD
J Neuroimmune Pharmacol; 2021 Mar; 16(1):48-58. PubMed ID: 33462776
[TBL] [Abstract][Full Text] [Related]
17. Purinergic signaling elements are correlated with coagulation players in peripheral blood and leukocyte samples from COVID-19 patients.
Schultz IC; Bertoni APS; Wink MR
J Mol Med (Berl); 2022 Apr; 100(4):569-584. PubMed ID: 35091759
[TBL] [Abstract][Full Text] [Related]
18. Purinergic signaling in liver disease.
Vaughn BP; Robson SC; Longhi MS
Dig Dis; 2014; 32(5):516-24. PubMed ID: 25034284
[TBL] [Abstract][Full Text] [Related]
19. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients.
Pietrobon AJ; Andrejew R; Custódio RWA; Oliveira LM; Scholl JN; Teixeira FME; de Brito CA; Glaser T; Kazmierski J; Goffinet C; Turdo AC; Yendo T; Aoki V; Figueiró F; Battastini AM; Ulrich H; Benard G; Duarte AJDS; Sato MN
Front Immunol; 2022; 13():1012027. PubMed ID: 36248842
[TBL] [Abstract][Full Text] [Related]
20. The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.
Ferrari D; Rubini M; Burns JS
Front Immunol; 2022; 13():904419. PubMed ID: 35784277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
